Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Patients with non-small cell lung cancer now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors.
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.
OTraces, Inc., a molecular diagnostics company specializing in early cancer detection, has announced completion of a preliminary study for detection of pancreatic cancer.
While researchers have a basic understanding of how primary cancer cells grow, less is known about metastasis, the deadly process by which cancers spread.
Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.
When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better.
Three beagles successfully showed they are capable of identifying lung cancer by scent, a first step in identifying specific biomarkers for the disease.
As advances in the treatment of non-small cell lung cancer (NSCLC) extend patients' lives, more of these patients are facing a different threat: adverse cardiovascular events, such as heart attacks and heart failure.
Roche Diagnostics today announced the launch of the VENTANA ROS1 Antibody, the first and only in vitro diagnostic ROS1 immunohistochemistry assay. The test detects the presence of ROS1 protein in tissue, and may be useful in identifying ROS1-positive lung cancer cases.
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years - and 25% of patients whose tumor cells had a specific protein lived at least that long.
The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.
For patients with operable non-small cell lung cancer, pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, multicenter clinical trial involving investigators at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and nine other research centers
Scientists at VCU Massey Cancer Center may have uncovered a primary method through which cancer cells exist undetected in an organism and received more than $1 million to investigate the potential for novel therapeutics that target and destroy cells in a specific state of tumor dormancy.
Patients who do not smoke are at an increased risk of lung cancer due to air pollution, warns PHE. These patients are often overlooked and diagnosed late, with poor outcomes.
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machines identify cancers--and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
University of Texas at Dallas scientists have demonstrated that the growth rate of the majority of lung cancer cells relates directly to the availability of a crucial oxygen-metabolizing molecule.
A deep-learning model developed using serial image scans of tumors from patients with non-small cell lung cancer (NSCLC) predicted treatment response and survival outcomes better than standard clinical parameters.
The recent emergence of immunotherapy has marked a sea change in research and care for many forms of cancer, bringing new hope to patients and families around the world. For those who respond to treatment, the results can be dramatic.
study from the University of Southern California, Keck School of Medicine, sought to examine possible health disparities in the treatment of lung cancer within the Asian community in the U.S.